Alcon Announces New Time and Motion Study Results Supporting Superior Efficiency* for Cataract and Vitreoretinal Surgery with ...

LumiThera's key innovation is a device for use by ophthalmologists that improves vision and slows its loss, with a focus on ...

In addition to the proxy statement, STAAR has reached out to all stockholders to ask for their vote to adopt the merger ...

The studies compared the Unity Vitreoretinal Cataract System (VCS) to the Constellation Vision System and the ...

In conjunction with the definitive proxy filing, Staar (STAA) is mailing the following letter to Staar stockholders: “On August 5, 2025, we ...

Alcon (ALC) announced results from time and motion studies demonstrating efficiency with Unity Vitreoretinal Cataract System for vitreoretinal and ...

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it has filed its ...

Alcon (NYSE: ALC) shares registered just barely in the plus column Tuesday. The company, purporting to be the global leader in eye care dedicated to helping people see brilliantly, announced results ...

Some claims have been dismissed in the suit, which also involves Warner Bros., about imagery used at a 2024 Tesla event—but ...

Investing.com - STAAR Surgical Company (NASDAQ:STAA)向Alcon AG (NYSE:ALC)的有争议的出售案在其最大股东采取正式步骤发起代理权争夺以阻止每股28美元的合并后进一步升级。

Part of Alcon's motivations for continuing to pursue the lawsuit relates to an upcoming TV series based on the movie. The company expressed that it wants to distance itself from Tesla and Elon Musk.

STAAR Surgical Company’s (NASDAQ:STAA) contested sale to Alcon AG (NYSE:ALC) has escalated after its largest shareholder took the first formal step toward a proxy fight to defeat the $28-per-share ...